The NRX-1074 intravenous form demonstrated antidepressant efficacy in an initial single-dose Phase II study, said Allergan. Naurex president and CEO Norbert Riedel said: "We recognised that Allergan's deep commitment and experience in mental health position them particularly well to progress these programmes through further clinical development and into commercialisation."